SCHEMBL6538765

SCHEMBL6538765

Cc1csc(-c2cc(-c3ccc(=O)n(C(C)C)n3)c(-c3ccccc3)nc2N)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.40
ADORA2A P29274 5/20 0.35
ADORA1 P30542 3/20 0.35
GABRA1 P14867 3/20 0.35
GABRG2 P18507 3/20 0.35
GABRB3 P28472 3/20 0.35
GABRA3 P34903 3/20 0.35
GABRA2 P47869 3/20 0.35
GLA P06280 1/20 0.35
P2RY6 Q15077 1/20 0.35
GABRA5 P31644 1/20 0.35
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
POLB P06746 2/20 0.34
RET P07949 2/20 0.33
NTRK1 P04629 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538453 0.91 RXFP1 (0.38) P2RY6ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6538477 0.86 ADORA2A (0.38) ADORA2AADORA1P2RY6PDE1APDE1B
SCHEMBL5149253 0.85 MET (0.39) METADORA2AADORA1P2RY6PDE1A
SCHEMBL6539119 0.82 ADORA2A (0.36) ADORA2AP2RY6PDE1APDE1BPDE1C
SCHEMBL6538926 0.80 POLB (0.39) ADORA2AADORA1P2RY6PDE1APDE1B
SCHEMBL6539038 0.80 ADORA2A (0.36) ADORA2AP2RY6PDE1APDE1BPDE1C
SCHEMBL6538908 0.80 SRC (0.35) ADORA2APDE1APDE1BPDE1CPOLB
SCHEMBL6538806 0.79 PDE1A (0.42) ADORA2AADORA1P2RY6PDE1APDE1B
SCHEMBL6538474 0.78 RET (0.41) ADORA2AADORA1PDE1APDE1BPDE1C
SCHEMBL6538517 0.78 AKT1 (0.39) ADORA2AADORA1ALDH1A1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 MET 4130/4885ADORA2A 2/4885ADORA1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.